Advertisement
Product › Details
Copaxone®
Next higher product group | glatiramer | |
Status | 1998-01-01 sales start | |
Organisation | Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) | |
Group | Teva (Group) | |
Original research | Weizmann Institute of Science | |
Record changed: 2023-07-10 |
Advertisement
More documents for immuno modulatory compound (IMO)
- [1] Vertex Pharmaceuticals Inc.. (4/10/24). "Press Release: Vertex Enters into Agreement to Acquire Alpine Immune Sciences". Boston, MA & Seattle, WA....
- [2] Immunic, Inc.. (1/5/24). "Press Release: Immunic, Inc. Announces Private Placement of up to $240 Million". New York, NY....
- [3] Odyssey Therapeutics, Inc.. (12/5/23). "Press Release: Odyssey Therapeutics Announces $101 Million Series C Financing". Boston, MA....
- [4] Immunic, Inc.. (11/2/23). "Press Release: Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts". New York, NY....
- [5] AiCuris Anti-infective Cures AG. (7/6/23). "Press Release: AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients". Wuppertal....
- [6] Ventus Therapeutics, Inc.. (9/29/22). "Press Release: Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program". Waltham, MA & Montréal, QC....
- [7] Kupando GmbH. (9/26/22). "Press Release: Kupando Raises €13 Million in Series A Funding Round". Schönefeld....
- [8] Immunic, Inc.. (7/6/22). "Press Release: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén". New York, NY....
- [9] Immunic, Inc.. (6/2/22). "Press Release: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update". New York, NY....
- [10] Artax Biopharma, Inc.. (5/11/22). "Press Release: Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases". Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top